Head-to-head · free
Acumen Pharmaceuticals vs Toyota Motor Corporation
ABOS vs TM — return on capital, cash generation, margins and balance sheet side by side.
ABOS
1 / 2
measures where ABOS leads
TM
1 / 2
measures where TM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABOS · FY2025 | TM |
|---|---|---|
| Revenue | — | — |
| Net income | (121.3M) | — |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | 3.6% |
| Return on equity | -96.2% | 10.1% |
| Gross margin | — | 16.7% |
| Operating margin | — | 7.4% |
| Net debt / EBITDA | 0.18x | 4.84x |
Figures are as reported by each company; latest fiscal year shown.
Where Acumen Pharmaceuticals's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free